Lawlor D Kirk, Moist Louise, DeRose Guy, Harris Kenneth A, Lovell Marjorie B, Kribs Stewart W, Elliot James, Forbes Thomas L
Division of Vascular Surgery, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada.
Ann Vasc Surg. 2007 Sep;21(5):593-7. doi: 10.1016/j.avsg.2007.07.006.
Presently, only hydration and N-acetylcysteine have been shown to be effective in decreasing the incidence of radiographic contrast-induced nephropathy. We investigated the role of N-acetylcysteine and various hydration protocols in vascular surgery patients undergoing angiography. A single-center, randomized, placebo-controlled trial was conducted in patients with stable, preexisting renal dysfunction undergoing elective, outpatient angiography. Patients were randomized to outpatient oral hydration and N-acetylcysteine, inpatient hydration plus N-acetylcysteine, or our standard therapy of inpatient intravenous hydration alone. Two of twenty-eight (7%) patients who received outpatient oral hydration and N-acetylcysteine developed contrast-induced nephropathy, while two of 25 (8%) who recieved inpatient hydration plus N-acetylcysteine developed contrast-induced nephropathy and two of 25 (8%) who received standard therapy of inpatient intravenous hydration alone developed contrast-induced nephropathy. There was no statistical difference in incidence of contrast-induced nephropathy between the groups. No statistically significant independent risk factors were identified among the patients who developed contrast-induced nephropathy. N-Acetylcysteine did not confer additional benefit to patients treated with inpatient intravenous hydration. Outpatient oral hydration plus N-acetylcysteine was as effective at preventing contrast-induced nephropathy as inpatient therapies and avoided costly hospital admission.
目前,仅补液和N-乙酰半胱氨酸已被证明可有效降低造影剂诱导的肾病的发生率。我们研究了N-乙酰半胱氨酸和各种补液方案在接受血管造影的血管外科手术患者中的作用。在患有稳定的、已存在的肾功能不全且接受择期门诊血管造影的患者中进行了一项单中心、随机、安慰剂对照试验。患者被随机分为门诊口服补液加N-乙酰半胱氨酸组、住院补液加N-乙酰半胱氨酸组或我们仅采用住院静脉补液的标准治疗组。接受门诊口服补液加N-乙酰半胱氨酸的28例患者中有2例(7%)发生了造影剂诱导的肾病,接受住院补液加N-乙酰半胱氨酸的25例患者中有2例(8%)发生了造影剂诱导的肾病,而仅接受住院静脉补液标准治疗的25例患者中有2例(8%)发生了造影剂诱导的肾病。各组之间造影剂诱导的肾病发生率无统计学差异。在发生造影剂诱导的肾病的患者中未发现统计学上显著的独立危险因素。N-乙酰半胱氨酸对接受住院静脉补液治疗的患者没有额外益处。门诊口服补液加N-乙酰半胱氨酸在预防造影剂诱导的肾病方面与住院治疗同样有效,且避免了昂贵的住院费用。